PUBLISHER: TechNavio | PRODUCT CODE: 1916083
PUBLISHER: TechNavio | PRODUCT CODE: 1916083
Global Glp 1 Analogues Market 2025-2029
The global glp 1 analogues market is forecasted to grow by USD 100084.7 mn during 2024-2029, accelerating at a CAGR of 25.3% during the forecast period. The report on the global glp 1 analogues market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of type 2 diabetes and obesity, growing awareness and diagnosis of metabolic disorders, favorable clinical outcomes and expanding indications.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2029 |
| Series Year | 2025-2029 |
| Growth Momentum | Accelerate |
| YOY 2025 | 24.1% |
| CAGR | 25.3% |
| Incremental Value | $100084.7 mn |
Technavio's global glp 1 analogues market is segmented as below:
By Application
- Type 2 diabetes mellitus
- Obesity management
- Cardiovascular diseases
By Route Of Administration
- Subcutaneous injection
- Oral administration
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the development of multi agonist therapies as one of the prime reasons driving the global glp 1 analogues market growth during the next few years. Also, expansion of indications beyond diabetes and shift towards oral and longer acting formulations will lead to sizable demand in the market.
The report on the global glp 1 analogues market covers the following areas:
- Global glp 1 analogues market sizing
- Global glp 1 analogues market forecast
- Global glp 1 analogues market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global glp 1 analogues market vendors that include Amgen Inc., Amneal Pharmaceuticals Inc., Ascendis Pharma AS, AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Innovent Biologics Inc., Johnson and Johnson Services, LG Chem Ltd., Merck and Co. Inc., Novo Nordisk AS, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd.. Also, the global glp 1 analogues market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
5 Historic Market Size
- 5.1 Global GLP 1 Analogues Market 2019 - 2023
- Historic Market Size - Data Table on Global GLP 1 Analogues Market 2019 - 2023 ($ million)
- 5.2 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ million)
- 5.3 Route of Administration segment analysis 2019 - 2023
- Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
- 5.4 Distribution Channel segment analysis 2019 - 2023
- Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global GLP 1 analogues market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
8 Market Segmentation by Application
- 8.1 Market segments
- 8.2 Comparison by Application
- 8.3 Type 2 diabetes mellitus - Market size and forecast 2024-2029
- 8.4 Obesity management - Market size and forecast 2024-2029
- 8.5 Cardiovascular diseases - Market size and forecast 2024-2029
- 8.6 Market opportunity by Application
- Market opportunity by Application ($ million)
9 Market Segmentation by Route of Administration
- 9.1 Market segments
- 9.2 Comparison by Route of Administration
- 9.3 Subcutaneous injection - Market size and forecast 2024-2029
- 9.4 Oral administration - Market size and forecast 2024-2029
- 9.5 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
10 Market Segmentation by Distribution Channel
- 10.1 Market segments
- 10.2 Comparison by Distribution Channel
- 10.3 Hospital pharmacies - Market size and forecast 2024-2029
- 10.4 Retail pharmacies - Market size and forecast 2024-2029
- 10.5 Online pharmacies - Market size and forecast 2024-2029
- 10.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- 12.3.1 US - Market size and forecast 2024-2029
- 12.3.2 Canada - Market size and forecast 2024-2029
- 12.3.3 Mexico - Market size and forecast 2024-2029
- 12.4 Europe - Market size and forecast 2024-2029
- 12.4.1 Germany - Market size and forecast 2024-2029
- 12.4.2 UK - Market size and forecast 2024-2029
- 12.4.3 France - Market size and forecast 2024-2029
- 12.4.4 Italy - Market size and forecast 2024-2029
- 12.4.5 Spain - Market size and forecast 2024-2029
- 12.4.6 Russia - Market size and forecast 2024-2029
- 12.4.7 The Netherlands - Market size and forecast 2024-2029
- 12.5 Asia - Market size and forecast 2024-2029
- 12.5.1 China - Market size and forecast 2024-2029
- 12.5.2 India - Market size and forecast 2024-2029
- 12.5.3 Japan - Market size and forecast 2024-2029
- 12.5.4 South Korea - Market size and forecast 2024-2029
- 12.5.5 Indonesia - Market size and forecast 2024-2029
- 12.5.6 Thailand - Market size and forecast 2024-2029
- 12.5.7 Singapore - Market size and forecast 2024-2029
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- 12.6.1 Brazil - Market size and forecast 2024-2029
- 12.6.2 Australia - Market size and forecast 2024-2029
- 12.6.3 UAE - Market size and forecast 2024-2029
- 12.6.4 South Africa - Market size and forecast 2024-2029
- 12.6.5 Saudi Arabia - Market size and forecast 2024-2029
- 12.6.6 Turkey - Market size and forecast 2024-2029
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Increasing prevalence of type 2 diabetes and obesity
- Growing awareness and diagnosis of metabolic disorders
- Favorable clinical outcomes and expanding indications
- 13.2 Market challenges
- High cost of therapy and reimbursement challenges
- Side effects and patient tolerability
- Competition from pipeline drugs and alternative therapies
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Development of multi agonist therapies
- Expansion of indications beyond diabetes
- Shift towards oral and longer acting formulations
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.5 Amneal Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc. - Overview
- Amneal Pharmaceuticals Inc. - Business segments
- Amneal Pharmaceuticals Inc. - Key news
- Amneal Pharmaceuticals Inc. - Key offerings
- Amneal Pharmaceuticals Inc. - Segment focus
- SWOT
- 15.6 Ascendis Pharma AS
- Ascendis Pharma AS - Overview
- Ascendis Pharma AS - Product / Service
- Ascendis Pharma AS - Key offerings
- SWOT
- 15.7 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- SWOT
- 15.8 Boehringer Ingelheim GmbH
- Boehringer Ingelheim GmbH - Overview
- Boehringer Ingelheim GmbH - Product / Service
- Boehringer Ingelheim GmbH - Key news
- Boehringer Ingelheim GmbH - Key offerings
- SWOT
- 15.9 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key offerings
- SWOT
- 15.10 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.11 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.12 Innovent Biologics Inc.
- Innovent Biologics Inc. - Overview
- Innovent Biologics Inc. - Product / Service
- Innovent Biologics Inc. - Key offerings
- SWOT
- 15.13 Johnson and Johnson Services
- Johnson and Johnson Services - Overview
- Johnson and Johnson Services - Business segments
- Johnson and Johnson Services - Key news
- Johnson and Johnson Services - Key offerings
- Johnson and Johnson Services - Segment focus
- SWOT
- 15.14 LG Chem Ltd.
- LG Chem Ltd. - Overview
- LG Chem Ltd. - Business segments
- LG Chem Ltd. - Key news
- LG Chem Ltd. - Key offerings
- LG Chem Ltd. - Segment focus
- SWOT
- 15.15 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.16 Novo Nordisk AS
- Novo Nordisk AS - Overview
- Novo Nordisk AS - Business segments
- Novo Nordisk AS - Key offerings
- Novo Nordisk AS - Segment focus
- SWOT
- 15.17 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.18 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Product / Service
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
